ArticleLeukemia2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Open access · greenAbstract readLetter
In one paragraph
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.American journal of hematology · 2026Review
- [Germline DDX41 mutations and myelodysplastic neoplasms].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026Review
- Germline DDX41 Variants: Current Understanding and Future Directions.Current hematologic malignancy reports · 2026Review
- Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies.Cancers · 2026Review
- DDX41-Mutated AML: A Case Report and Perspectives.JCO precision oncology · 2026Article
- Advances and challenges in the treatment of myelodysplastic syndromes.Experimental hematology & oncology · 2025Review
- Role of reactive oxygen species in myelodysplastic syndromes.Cellular & molecular biology letters · 2024Review
- Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.Biomedicines · 2023Article
- Favorable outcomes ofEJHaem · 2023Article
- Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Review
- Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies.Journal of genetic counseling · 2023Article
- Current Understanding ofCancers · 2023Review
- Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.Current hematologic malignancy reports · 2022Review
- Article
- Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations.Biomedicines · 2022Review
- Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process.Diagnostics (Basel, Switzerland) · 2022Review
- Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.Blood advances · 2022Article
- Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.Frontiers in oncology · 2022Review
- The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.Current hematologic malignancy reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 4 countries.
E NegoroDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
T RadivoyevitchQuantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
C PolprasertDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
V AdemaJosep Carreras Leukaemia Research Institute, Barcelona, Spain.
N HosonoDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
H MakishimaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
B PrzychodzenDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
C HirschDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
M J ClementeDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
A NazhaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
V SantiniHematology Unit, AOU Careggi, University of Florence, Firenze, Italy.
K L McGrawDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
A F ListDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
F SoleJosep Carreras Leukaemia Research Institute, Barcelona, Spain.
M A SekeresDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
J P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic · USJosep Carreras Leukaemia Research Institute · ESMoffitt Cancer Center · USKyoto University · JPUniversity of Florence · IT
Funding
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1MInvestigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9MNHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overChromosomes, Human, Pair 5Cohort StudiesFemaleHumansImmunologic FactorsLenalidomideMaleMiddle AgedMutationMyelodysplastic SyndromesThalidomideYoung AdultImmunologic FactorsLenalidomideThalidomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.